glp 1 ckd Frontiers Kidney and Cardiovascular Outcomes Among

Joo JH, et al

In this phase 2 study, 48 patients with obesity or who were overweight and also had alcohol use disorder were randomly assigned either a placebo or a low dose of semaglutide, with researchers testing how much the drug changed drinking habits after about two months

Semaglutide is a single GLP-1 agonist

Pancreatic polypeptide: a unique model for vagal control of endocrine systems

The use of nalbuphine, a blocker of - and -opioid receptors, also disrupted the effect of GLP-1RAs on reducing TNF- levels, highlighting the essential role of these opioid receptors in the anti-inflammatory effects mediated by GLP-1RAs